GB1532803A - Cancer diagnostic agents - Google Patents

Cancer diagnostic agents

Info

Publication number
GB1532803A
GB1532803A GB4220875A GB4220875A GB1532803A GB 1532803 A GB1532803 A GB 1532803A GB 4220875 A GB4220875 A GB 4220875A GB 4220875 A GB4220875 A GB 4220875A GB 1532803 A GB1532803 A GB 1532803A
Authority
GB
United Kingdom
Prior art keywords
target
attaching
body fluid
blood serum
globulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4220875A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB4220875A priority Critical patent/GB1532803A/en
Publication of GB1532803A publication Critical patent/GB1532803A/en
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1532803 Target attaching globulins S BOGOCH 15 Oct 1975 42208/75 Heading C3H Compounds, termed target-attaching globulins, are claimed per se and are characterized by (I) being soluble in aqueous buffered solutions; (II) forming a single line precipitate with recognins as hereinbefore defined, in Ouchterlony gel diffusion tests; (III) being non-dialysable in transparent cellulose membranes; (IV) being retained in filters which retain molecules having a molecular weight greater than 25,000; (V) having molecular weights in different states of aggregation as determined by thin layer gel chromatography or approximately 50,000 and multiples thereof in the macroglobulin range; (VI) having a spectrophotometric absorption peak wave length of 280 mu.; and (VII) attaching to glioma tumor cells preferentially in a histological section of brain tumor. A subgroup of compounds termed slow target-attaching globulin may be further characterized by being produced in greater amounts in vitro from a given volume of blood serum or other body fluid from a source containing malignant tumors than from a source free from such tumors, by reaction of said blood serum or other body fluid with a target reagent at a low temperature, to prevent degradative reactions, and treating the resulting material with dilute acid to cleave the desired product therefrom. Other compounds termed fast-target-attaching globulin may be further characterized by being produced in equal amounts in vitro from a given volume of blood serum or other body fluid from a source containing malignant tumors and from a source free from such tumors, by reaction of blood serum or other body fluid with a target reagent as hereinbefore defined, at a lower temperature to prevent degradative reactions, and treating the resulting material with dilute acid to cleave the desired product therefrom. The target-attaching globulins may be prepared by (a) reacting blood serum or other body fluid with a target reagent at approximately 4‹ C. to prevent degradative reactions; and (b) treating the resulting material with acid to cleave the desired product therefrom. Step (a) is preferably carried out for a period of two hours or greater.
GB4220875A 1975-10-15 1975-10-15 Cancer diagnostic agents Expired GB1532803A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB4220875A GB1532803A (en) 1975-10-15 1975-10-15 Cancer diagnostic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4220875A GB1532803A (en) 1975-10-15 1975-10-15 Cancer diagnostic agents

Publications (1)

Publication Number Publication Date
GB1532803A true GB1532803A (en) 1978-11-22

Family

ID=10423331

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4220875A Expired GB1532803A (en) 1975-10-15 1975-10-15 Cancer diagnostic agents

Country Status (1)

Country Link
GB (1) GB1532803A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006357A1 (en) * 1978-06-16 1980-01-09 Sankyo Company Limited Composition and method for detecting gastric cancer
EP0007214A1 (en) * 1978-07-07 1980-01-23 Samuel Dr. Bogoch Product for detecting the presence of cancerous or malignant tumor cells
EP0015755A2 (en) * 1979-03-09 1980-09-17 Samuel Dr. Bogoch Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006357A1 (en) * 1978-06-16 1980-01-09 Sankyo Company Limited Composition and method for detecting gastric cancer
EP0007214A1 (en) * 1978-07-07 1980-01-23 Samuel Dr. Bogoch Product for detecting the presence of cancerous or malignant tumor cells
EP0015755A2 (en) * 1979-03-09 1980-09-17 Samuel Dr. Bogoch Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors
EP0015755A3 (en) * 1979-03-09 1980-12-10 Samuel Dr. Bogoch Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors

Similar Documents

Publication Publication Date Title
Blakeslee et al. Immunofluorescence using dichlorotriazinylaminofluorescein (DTAF) I. Preparation and fractionation of labelled IgG
Carpenter et al. Intermolecular cross-linking of monomeric proteins and cross-linking of oligomeric proteins as a probe of quaternary structure: application to leucine aminopeptidase (bovine lens)
US4269605A (en) Method and kit for separation of glycoproteins
Ji A novel approach to the identification of surface receptors. The use of photosensitive hetero-bifunctional cross-linking reagent.
Torchilin et al. Immobilization of enzymes on slowly soluble carriers
Whittaker et al. The hydrolysis of succinyldicholine by cholinesterase
Needham et al. The hydrogen-ion concentration and the oxidation-reduction potential of the cell-interior: A micro-injection study
Conrad et al. Characterization of the target cell receptor for IgE—I. Solubilization of IgE-receptor complexes from rat mast cells and rat basophilic leukemia cells
EP0221748A3 (en) A process for the production of human antibodies
GB2024829A (en) Method and Product for Separation of Glycoproteins
Guthrow et al. Specific photoaffinity labeling of the adenosine 3′: 5′-cyclic monophosphate receptor in intact ghosts from human erythrocytes
IL42105A (en) Process for determination of triiodothyronine
Altmann et al. Activation of enzymes by chelating agents
Kahn et al. Gd (-) Abrami a deficient G-6PD variant with hemizygous expression in blood cells of a woman with primary myelofibrosis
GB1532803A (en) Cancer diagnostic agents
Coman Reduction in cellular adhesiveness upon contact with a carcinogen
Baddiley et al. Synthesis of adenosine triphosphate
Bodian et al. Phosphatase Activity in Chromatolytic Nerve Cells.
Mukaiyama et al. Catalytic and stereoselective glycosylation with disarmed glycosyl fluoride by using a combination of stannous (II) chloride (SnCl2) and silver tetrakis (pentafluorophenyl) borate [AgB (C6F5) 4] as a catalyst
Ludowieg et al. A method for analysis of amino sugars: specificity and mechanism of the reaction
EP0280135B1 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
Frank et al. Diazoacetyl choline bromide
Wolfson Location of alpha-2-globulin by demonstration of alkaline phosphatase during paper electrophoresis
Parker et al. Periodate induced lymphocyte transformation. I. Inhibition by sulfhydryl reducing agents and sugars
Yagi et al. Separation of flavins by ion-exchange resins

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee
728C Application made for restoration (sect. 28/1977)
728A Order made restoring the patent (sect. 28/1977)
PCNP Patent ceased through non-payment of renewal fee